Cargando…

Real-World Patient Characteristics and Treatment Patterns of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients with Cancer: A Multicenter Retrospective Chart Review Study

Background and Objectives: Naldemedine is a peripherally acting μ-opioid receptor antagonist that improves opioid-induced constipation. Although clinical trials have excluded patients with poor performance status (PS) and those started on naldemedine early after opioid initiation, clinical practice...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hiruta, Eriko, Fujita, Yukiyoshi, Imai, Hisao, Masuno, Takashi, Yamazaki, Shigeki, Tanaka, Hajime, Kamiya, Teruhiko, Ito, Masako, Takei, Satoshi, Matsuura, Masato, Nishiba, Hiromi, Mogi, Junnosuke, Kotake, Mie, Koizuka, Shiro, Minato, Koichi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8625056/ https://www.ncbi.nlm.nih.gov/pubmed/34833451 http://dx.doi.org/10.3390/medicina57111233

Ejemplares similares

Efficacy and Safety of Naldemedine for Patients with Cancer with Opioid-Induced Constipation in Clinical Practice: A Real-World Retrospective Study
por: Nishiba, Hiromi, et al.
Publicado: (2022)

A Retrospective Study of the Efficacy and Safety of Naldemedine for Treatment of Opioid-Induced Constipation in Patients with Hepatobiliary Pancreatic Cancer
por: Kamiya, Teruhiko, et al.
Publicado: (2023)

A retrospective study of the efficacy and safety of naldemedine for opioid‐induced constipation in thoracic cancer patients
por: Imai, Hisao, et al.
Publicado: (2022)

Update on the role of naldemedine in opioid-induced constipation in patients with chronic noncancer pain
por: BouSaba, Joelle, et al.
Publicado: (2022)

Safety and efficacy of naldemedine in cancer patients with opioid-induced constipation: a pooled, subgroup analysis of two randomised controlled studies
por: Osaka, Iwao, et al.
Publicado: (2019)

Spotlight on naldemedine in the treatment of opioid-induced constipation in adult patients with chronic noncancer pain: design, development, and place in therapy
por: Stern, Emily K, et al.
Publicado: (2018)

Effectiveness of Naldemedine Compared with Magnesium Oxide in Preventing Opioid-Induced Constipation: A Randomized Controlled Trial
por: Ozaki, Anna, et al.
Publicado: (2022)

Factors associated with non-response to naldemedine for opioid-induced constipation in cancer patients: A subgroup analysis
por: Kanbayashi, Yuko, et al.
Publicado: (2022)

Naldemedine is effective in the treatment of opioid-induced constipation in patients with chronic non-cancer pain who had a poor response to laxatives
por: Hale, Martin E., et al.
Publicado: (2021)

Naldemedine in Japanese patients with opioid-induced constipation and chronic noncancer pain: open-label Phase III studies
por: Saito, Yoji, et al.
Publicado: (2018)

Post-marketing surveillance of the safety and effectiveness of naldemedine in the management of opioid-induced constipation in patients with cancer pain in Japan
por: Takata, Keiko, et al.
Publicado: (2022)

Randomized phase III and extension studies: efficacy and impacts on quality of life of naldemedine in subjects with opioid-induced constipation and cancer
por: Katakami, N, et al.
Publicado: (2018)

Naldemedine: A New Option for OIBD
por: Coluzzi, Flaminia, et al.
Publicado: (2020)

Effects of Sex and Seasonal Climatic Changes on the Risk of Incidence of Anti-EGFR Therapy-Induced Rash in Cancer Patients: A Retrospective Study
por: Arai, Takahiro, et al.
Publicado: (2021)

Onset of action of naldemedine in the treatment of opioid-induced constipation in patients with chronic noncancer pain: results from 2 randomized, placebo-controlled, phase 3 trials
por: Wild, James, et al.
Publicado: (2019)

A Renal Impairment Subgroup Analysis of the Safety and Efficacy of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients with Chronic Non-Cancer Pain Receiving Opioid Therapy
por: Webster, Lynn R, et al.
Publicado: (2020)

Pharmacologic effects of naldemedine, a peripherally acting μ‐opioid receptor antagonist, in in vitro and in vivo models of opioid‐induced constipation
por: Kanemasa, Toshiyuki, et al.
Publicado: (2019)

Population Pharmacokinetics and Exposure-Response Relationships of Naldemedine
por: Kubota, Ryuji, et al.
Publicado: (2018)

Long-term use of naldemedine in the treatment of opioid-induced constipation in patients with chronic noncancer pain: a randomized, double-blind, placebo-controlled phase 3 study
por: Webster, Lynn R., et al.
Publicado: (2018)

Naldemedine Improves Patient-Reported Outcomes of Opioid-Induced Constipation in Patients with Chronic Non-Cancer Pain in the COMPOSE Phase 3 Studies
por: Camilleri, Michael, et al.
Publicado: (2021)

A Phase 2b, Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients with Chronic Noncancer Pain
por: Webster, Lynn R, et al.
Publicado: (2017)

Safety and Efficacy of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients with Chronic Non-Cancer Pain Receiving Opioid Therapy: A Subgroup Analysis of Patients ≥ 65 Years of Age
por: Wild, James, et al.
Publicado: (2020)

Intrapericardial carboplatin in the management of malignant pericardial effusion in breast cancer: a pilot study
por: Kotake, Mie, et al.
Publicado: (2019)

Fentanyl/naldemedine: Diarrhoea and decreased peristalsis: case report
Publicado: (2021)

The Influence of Renal or Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Naldemedine
por: Fukumura, Kazuya, et al.
Publicado: (2019)

Topotecan monotherapy for the treatment of relapsed small cell lung cancer in elderly patients: A retrospective analysis
por: Imai, Hisao, et al.
Publicado: (2018)

Real-World Evidence for the Safety and Effectiveness of Naldemedine in the Management of Opioid-Induced Constipation in Patients With Cancer Pain: Post-hoc Subgroup Analysis of Post-marketing Surveillance in Japan
por: Naya, Noriyuki, et al.
Publicado: (2023)

Post‐progression survival is highly linked to overall survival in patients with non‐small‐cell lung cancer harboring sensitive EGFR mutations treated with first‐line epidermal growth factor receptor‐tyrosine kinase inhibitors
por: Imai, Hisao, et al.
Publicado: (2019)

Rationale and design of a multicenter, double-blinded, randomized, placebo-controlled trial to investigate the effects of naldemedine on opioid-induced constipation for patients with cancer pain: A study protocol
por: Higashibata, Takahiro, et al.
Publicado: (2022)

Opioid therapy duration before naldemedine treatment is a significant independent risk of diarrhea: a retrospective cohort study
por: Okamoto, Akiharu, et al.
Publicado: (2021)

The Treatment of Constipation
por: Allison, S. R.
Publicado: (1935)

The Treatment of Constipation
por: Taylor, Seymour
Publicado: (1909)

Treatment of Constipation
por: Toepel, Theodore
Publicado: (1906)

Comparing the effectiveness of magnesium oxide and naldemedine in preventing opioid-induced constipation: a proof of concept, single institutional, two arm, open-label, phase II, randomized controlled trial: the MAGNET study
por: Ozaki, Anna, et al.
Publicado: (2020)

Naldemedine-induced Opioid Withdrawal Syndrome in a Patient with Breast Cancer without Brain Metastasis
por: Ishii, Koji, et al.
Publicado: (2019)

Low‐Dose Olanzapine Plus Granisetron and Dexamethasone for Carboplatin‐Induced Nausea and Vomiting in Patients with Thoracic Malignancies: A Prospective Multicenter Phase II Trial
por: Sakai, Chizuru, et al.
Publicado: (2021)

Treatment of Constipation by Faradism
Publicado: (1888)

The Treatment of Constipation in Children
por: Dunlop, G. H. Melville
Publicado: (1909)

The Treatment of Habitual Constipation
Publicado: (1894)

The Treatment of Chronic Constipation
Publicado: (1892)

Cannot write session to /tmp/vufind_sessions/sess_sb809850amj5qej3k2lbrkebvq